[A22-14] Duvelisib (follicular lymphoma) - Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2022
Project no.:
A22-14
Commission:
Commission awarded on 02.02.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with follicular lymphoma that is refractory to at least 2 prior systemic therapies
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-13 | Duvelisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |